Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reduced levels of pulmonary surfactant in COVID-19 ARDS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hyperhidrosis and human leucocyte antigens in the Danish Blood Donor Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Humoral response to two doses of BNT162b2 vaccination in people with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

Vis graf over relationer

Cytokine-specific autoantibodies (c-aAbs) represent an emerging field in endogenous immunodeficiencies, and the immunomodulatory potential of c-aAbs is now well documented. Here, we investigated the hypothesis that c-aAbs affects inflammatory, immunoregulatory and injury-related processes and hence the clinical outcome of haematopoietic stem cell transplantation (HSCT). C-aAbs against IL-1α, IL-6, IL-10, IFNα, IFNγ and GM-CSF were measured in 131 HSCT recipients before and after (days + 7, + 14, + 28) HSCT and tested for associations with 33 different plasma biomarkers, leukocyte subsets, platelets and clinical outcomes, including engraftment, GvHD and infections. We found that c-aAb levels were stable over the course of HSCT, including at high titres, with few individuals seeming to acquire high-titre levels of c-aAbs. Both patients with stable and those with acquired high-titre c-aAb levels displayed significant differences in biomarker concentrations and blood cell counts pre-HSCT and at day 28, and the trajectories of these variables varied over the course of HSCT. No clinical outcomes were associated with high-titre c-aAbs. In this first study of c-aAbs in HSCT patients, we demonstrated that high-titre levels of c-aAb may both persist and emerge in patients over the course of HSCT and may be associated with altered immune biomarkers and cell profiles.

OriginalsprogEngelsk
Artikelnummer23971
TidsskriftScientific Reports
Vol/bind11
Udgave nummer1
Sider (fra-til)23971
ISSN2045-2322
DOI
StatusUdgivet - 14 dec. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 72155818